Status:
TERMINATED
Lamictal in the Treatment of Post-Herpetic Neuralgia
Lead Sponsor:
George Washington University
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
Neuralgia, Postherpetic
Eligibility:
All Genders
18-85 years
Phase:
PHASE2
PHASE3
Brief Summary
To assess the efficacy of Lamictal for the treatment of pain and reduction of allodynia in patients with post herpetic neuralgia.
Eligibility Criteria
Inclusion
- All patients will be over the age of 18,
- Need to have a diagnosis of Post-Herpetic Neuralgia,
- Minimum of 4 on the Likert Pain Scale,
- If currently taking TCA and/or Gabapentin, need to have been on stable dose for minimum of 4 weeks
Exclusion
- Currently on any antiepileptic drugs (AED), except for Gabapentin.
- Currently taking opioid or unwilling to washout prior to the study,
- Pregnant and lactating,
- Have active severe systemic disease,
- History of Stevens-Johnson syndrome or TEN,
- Clinically significant abnormal lab values,
- Known drug allergy to Lamictal,
- Patients on Fibrates (Tricor and Lopid),
- History of major psychiatric disturbance and substance abuse.
- Valproate due to increase chances of severe rash,
- Lidocaine Patch,
- Use of hormonal contraceptives (birth control pills, patch, ring, injection)
Key Trial Info
Start Date :
February 1 2005
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00295776
Start Date
February 1 2005
Last Update
March 13 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical Faculty Associates
Washington D.C., District of Columbia, United States, 20037